Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2016 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KEROS THERAPEUTICS INC | 8 | Q2 2024 | 12.8% |
FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
INHIBRX INC | 5 | Q4 2021 | 3.9% |
ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
ARGENX SE | 4 | Q3 2023 | 70.2% |
BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
TG THERAPEUTICS INC | 3 | Q4 2023 | 43.0% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-09-03 |
13F-HR | 2024-08-14 |
N-PX | 2024-07-30 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
4 | 2023-06-28 |
SC 13D/A | 2023-06-28 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.